Press Releases

 
Press Releases
  Date Title and Summary View
Nov 11, 2016
CRANBURY, N.J., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 012 (ATTRACT) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat compared with Enzyme Replacemen...
PDF
Nov 7, 2016
Strong Momentum for Galafold Launch in Europe and Further Global Regulatory Submissions Initial Data from Pompe Phase 1/2 Clinical Study on Track for 4Q16 CRANBURY, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announce...
PDF
Nov 1, 2016
CRANBURY, N.J., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced a conference call and live audio webcast on Monday, November 7, 2016 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2016. ...
PDF
Sep 22, 2016
CRANBURY, N.J., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable S...
PDF
Sep 13, 2016
CRANBURY, N.J., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch Global Healthcare Conference 2016 on Septe...
PDF
Sep 1, 2016
CRANBURY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will participate in a corporate overview and fireside chat at the Robert W. Baird & Co. 2016 Healthcare Conference in Ne...
PDF
Aug 31, 2016
CRANBURY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that 7 posters highlighting its Fabry program will be included in the Society for the Study of Inborn Errors of Metabolism's 2016 SSIEM Annual Symposium to be held Septem...
PDF
Aug 10, 2016
CRANBURY, N.J., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from the pivotal Phase 3 Study 011 (FACETS) evaluating the efficacy and safety of the oral pharmacological chaperone migalastat in individuals with Fabry disease were ...
PDF
Aug 9, 2016
Significant Progress with EU Galafold Launch and Regulatory Submissions Enrollment in Pompe Phase 1/2 Clinical Study on Track with Initial Data Expected in 2H16 Elevation of "Time to Wound Closure" as Co-Primary Endpoint in Ongoing Phase 3 Study of SD-101 for Epidermolysis Bullosa $130 Million in Equity and Debt Proceeds Since March...
PDF
Aug 3, 2016
Pre-Submission Meeting Completed with Pharmaceuticals and Medical Devices Agency (PMDA) in Japan PMDA Confirms That No Further Clinical Studies Are Needed for Submission CRANBURY, N.J., Aug. 03, 2016 (GLOBE NEWSWIRE) --  Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, plans to submit...
PDF
Page: FirstPrevious
3
... NextLast